| Not Yet Recruiting | Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test NCT07430410 | CorDx, Inc. | N/A |
| Not Yet Recruiting | Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) NCT07314905 | Unity Health Toronto | Phase 3 |
| Active Not Recruiting | Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A NCT07229807 | Guangdong Raynovent Biotech Co., Ltd | Phase 3 |
| Active Not Recruiting | Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A NCT07229820 | Guangdong Raynovent Biotech Co., Ltd | Phase 3 |
| Completed | Influenza A-associated Pulmonary Aspergillosis in Patients Admitted to the Intensive Care Unit in China NCT07330986 | Jianfeng Xie | — |
| Not Yet Recruiting | Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Se NCT07217639 | Aptitude Medical Systems | N/A |
| Active Not Recruiting | A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) NCT07128615 | AstraZeneca | Phase 1 / Phase 2 |
| Not Yet Recruiting | Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine NCT06800950 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 3 |
| Completed | Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescript NCT06734741 | InBios International, Inc. | — |
| Completed | Pharmacokinetics，Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza A NCT06656026 | Guangdong Raynovent Biotech Co., Ltd | Phase 2 |
| Completed | Covid Flu A/B and RSV 4 in 1 Diagnostic Test NCT07308158 | iHealth Labs inc | — |
| Completed | Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test NCT07190131 | iHealth Labs inc | — |
| Active Not Recruiting | Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine NCT06622590 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 1 |
| Recruiting | A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients NCT06672692 | DiaSorin Molecular LLC | N/A |
| Completed | Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations NCT06567860 | La Jolla Institute for Immunology | Phase 4 |
| Not Yet Recruiting | LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in S NCT06392451 | DiaSorin Molecular LLC | N/A |
| Completed | Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adop NCT06229444 | Evidation Health | N/A |
| Completed | Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Be NCT06207929 | Evidation Health | — |
| Unknown | A Prospective, Multicenter, Randomized Controlled Clinical Study on the Efficacy and Safety of Xuanfei Baidu G NCT06205641 | Capital Medical University | N/A |
| Unknown | Clinical Performance Study for EDAN's COVID-19/Flu A/Flu B/RSV Test Kits on Subjects Suspected of Respiratory NCT06175611 | EDAN Instruments Inc. | — |
| Completed | Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use NCT06124638 | Abbott Rapid Dx | N/A |
| Completed | Influenza Viral Challenge Study of CC-42344 in Healthy Participants NCT06160531 | Cocrystal Pharma, Inc. | Phase 2 |
| Completed | SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings NCT06191393 | Aptitude Medical Systems | N/A |
| Completed | Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel NCT06127108 | Abbott Rapid Dx | N/A |
| Unknown | FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol NCT05928507 | Baebies, Inc. | — |
| Unknown | H7HLAII DNA Influenza Vaccine NCT06046092 | Oslo University Hospital | Phase 1 |
| Completed | LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia NCT05897515 | DiaSorin Molecular LLC | N/A |
| Unknown | Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Re NCT05787444 | LumiraDx UK Limited | — |
| Completed | Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit NCT06008457 | Sequenom, Inc. | — |
| Completed | Project STARFISH - PRJ0002679 NCT05727202 | Thermo Fisher Scientific, Inc | — |
| Completed | MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study NCT05732610 | Medical Group Care, LLC | N/A |
| Completed | Performance Evaluation of the LumiraDX SARS-CoV-2 Ag Ultra and LumiraDX SARS-CoV-2 & Flu A/B Tests at Point of NCT05728970 | LumiraDx UK Limited | — |
| Completed | Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Device and the Panbio™ COVID- NCT05715515 | Abbott Rapid Dx | N/A |
| Completed | Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate N NCT05630365 | Abbott Rapid Dx | N/A |
| Terminated | A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza NCT05567783 | Vir Biotechnology, Inc. | Phase 2 |
| Completed | A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus NCT06385821 | NPO Petrovax | Phase 3 |
| Completed | Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel. NCT05354115 | Abbott Rapid Dx | N/A |
| Completed | CC-42344 Safety Study in Healthy Participants NCT05202379 | Cocrystal Pharma, Inc. | Phase 1 |
| Completed | Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessme NCT05268939 | LumiraDx UK Limited | N/A |
| Completed | Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel NCT05163730 | Abbott Rapid Diagnostics Jena GmbH | N/A |
| Active Not Recruiting | Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using NCT04896853 | NextCell Pharma Ab | Phase 1 |
| Completed | Effects of Integrative Medicine on Infectious Respiratory Diseases Including COVID-19 NCT04653727 | Charite University, Berlin, Germany | — |
| Completed | A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A NCT04683406 | Guangdong Raynovent Biotech Co., Ltd | Phase 3 |
| Terminated | Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml NCT04810949 | Hospital Clinica Nova | N/A |
| Completed | Home Testing of Respiratory Illness NCT04245800 | Evidation Health | — |
| Completed | Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A NCT04024137 | Guangdong Raynovent Biotech Co., Ltd | Phase 2 |
| Completed | Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines NCT03999554 | FluGen Inc | Phase 1 |
| Completed | Study to Assess Safety, Tolerability and Reactogenicity of Vaccine "UniFluVec" After Two Intranasal Administra NCT04650971 | Pharmenterprises Biotech LLC | Phase 1 |
| Completed | Study of VIR-2482 in Healthy Volunteers NCT04033406 | Vir Biotechnology, Inc. | Phase 1 |
| Completed | Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults NCT03743688 | Vanderbilt University Medical Center | — |
| Completed | The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac NCT03651544 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Phase 1 |
| Terminated | A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in NCT03381196 | Janssen Research & Development, LLC | Phase 3 |
| Unknown | Flufenamic Acid for Hospitalised Influenza Infection NCT03238612 | The University of Hong Kong | Phase 2 |
| Completed | Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Infl NCT03040141 | Visterra, Inc. | Phase 2 |
| Terminated | A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in NCT03376321 | Janssen Research & Development, LLC | Phase 3 |
| Unknown | Biomarkers Predicting Infectivity in an Experimental Human Influenza Model NCT03207152 | Duke University | Phase 1 |
| Terminated | A Study to Evaluate the Efficacy and Safety of CT-P27 in Acute Uncomplicated Influenza A Infection NCT03511066 | Celltrion | Phase 2 |
| Completed | A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults NCT02623322 | Genentech, Inc. | Phase 2 |
| Completed | Validation of the Ellume® Respirio Flu Test and the Ellume® eLab Flu Test for the Rapid Identification of Infl NCT02767414 | Ellume Pty Ltd | N/A |
| Completed | Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population NCT03196661 | Hualan Biological Bacterin Co. Ltd. | Phase 1 |
| Completed | Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B NCT02487173 | Ellume Pty Ltd | N/A |
| Completed | Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults H NCT02287467 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects NCT02342249 | Janssen Research & Development, LLC | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model NCT02071914 | Celltrion | Phase 2 |
| Completed | Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Fo NCT02071329 | Immune Targeting Systems Ltd | Phase 1 / Phase 2 |
| Completed | Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer NCT02067286 | IQuum, Inc. | — |
| Completed | Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers NCT02014870 | Immune Targeting Systems Ltd | Phase 1 |
| Completed | Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Adm NCT01701752 | Immune Targeting Systems Ltd | Phase 1 |
| Completed | Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1) NCT01677676 | Immune Targeting Systems Ltd | Phase 1 |
| Completed | Collection and Testing of Respiratory Samples NCT01302418 | QIAGEN Gaithersburg, Inc | — |
| Completed | Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza NCT01052480 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7 NCT00922259 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Convalescent Plasma Treatment in Severe 2009 H1N1 Infection NCT01306773 | The University of Hong Kong | N/A |
| Unknown | The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients NCT00987012 | Hillel Yaffe Medical Center | N/A |